Rabu, 15 Desember 2021

Omicron spreading at unprecedented rate: WHO, Europe News & Top Stories - The Straits Times

GENEVA (AFP) - The new coronavirus variant Omicron is spreading at an unprecedented rate, the WHO said on Tuesday (Dec 14), urging countries to act swiftly to rein in transmission and protect their health systems.

Since the new, heavily-mutated variant was first detected in southern Africa last month, it has been reported in 77 countries, WHO chief Tedros Adhanom Ghebreyesus told reporters.

But, he stressed, “the reality is that Omicron is probably in most countries, even if it hasn’t been detected yet.”

“Omicron is spreading at a rate we have not seen with any previous variant,” he said.

WHO expert Abdi Mahamud, meanwhile, told the press conference that modelling indicated that some countries in Europe – already battling a fierce fifth pandemic wave – could see Omicron become the dominant variant within days.

The warnings came amid growing evidence that the new variant might be better at skirting vaccine protections than previous ones.

A study published by Pfizer Tuesday showed that two doses of its Covid jabs offer around 70 per cent protection against severe disease from Omicron, compared to 93 per cent against earlier variants.

Data has also, meanwhile, indicated that the new variant might cause milder symptoms.

‘Very dangerous situation’

But WHO expert Bruce Aylward strenuously warned against “jumping to a conclusion that this is a mild disease.”

“If we go into a season like we’re going into now when a lot of people want to get together for the holiday season, and we have a more transmissible virus,” that we don’t actually know is milder, “we could be setting ourselves up for a very dangerous situation,” he warned.

Tedros also cautioned against “dismissing Omicron as mild,” pointing out that even if the variant does cause less severe disease, the sheer number of cases could once again overwhelm unprepared health systems.”

He called on countries to use all possible measures to rein in the spread, including scaling up vaccination, encouraging mask-wearing and physical distancing.

“Do it all. Do it consistently. Do it well.”

WHO emergencies director Michael Ryan also stressed that more data was needed to determine the severity of Omicron, urging countries to prepare to “deal with what is likely to happen, which is a large wave of cases.”

Those cases “may or may not be less severe, but... will in themselves generate pressure on the health system,” he said, insisting on the need to “reduce that pressure.”

‘Vaccine hoarding’

As countries scramble to deal with Omicron, Tedros voiced concern that many were rolling out booster vaccine doses to the general population, warning that this could deepen inequity in vaccine access between wealthy and poorer countries.

“WHO is concerned that such programmes will repeat the Covid-19 vaccine hoarding” seen previously this year, he said.

He said there was not yet enough data to show a third dose is needed to effectively protect healthy adults against the variant, although he said that “as we move forward, boosters could play an important role.”

At the same time, many vulnerable people in poorer countries have not yet received a single dose.

But Tedros pointed out on Tuesday that 41 countries have yet to vaccinate even 10 per cent of their populations.

“Let me be very clear: WHO is not against boosters. We’re against inequity. Our main concern is to save lives everywhere,” Tedros said.

“It’s a question of prioritisation,” he said.

“The order matters. Giving boosters to groups at low risk of severe disease or death simply endangers the lives of those at high risk who are still waiting for their primary doses because of supply constraints.”

Related Stories: 

Adblock test (Why?)


https://news.google.com/__i/rss/rd/articles/CBMiVWh0dHBzOi8vd3d3LnN0cmFpdHN0aW1lcy5jb20vd29ybGQvZXVyb3BlL29taWNyb24tc3ByZWFkaW5nLWF0LXVucHJlY2VkZW50ZWQtcmF0ZS13aG_SAQA?oc=5

2021-12-14 17:33:40Z
1191888452

Selasa, 14 Desember 2021

Pfizer COVID-19 vaccine protecting against hospitalisation during Omicron wave: Study - CNA

JOHANNESBURG: Two doses of Pfizer-BioNTech's COVID-19 vaccine appear to have given 70 per cent protection against hospitalisation in South Africa in recent weeks, a major real-world study on the potential impact of Omicron showed on Tuesday (Dec 14), as the country battles a spike in infections linked to the new variant.

The study released by South Africa's largest private health insurance administrator, Discovery Health, was based on more than 211,000 positive COVID-19 test results from Nov 15 to Dec 7, around 78,000 of which were attributed to Omicron.

The 78,000 results are not confirmed Omicron cases, meaning the study is not able to draw conclusive findings about the variant labelled "of concern" by the World Health Organization.

South African scientists have so far confirmed around 550 Omicron sequences, with the variant accounting for 78 per cent of sequences from November, more than the previously dominant Delta variant.

South Africa alerted the world to Omicron late last month, triggering alarm that it could cause another surge in global infections, and leading to the imposition of travel restrictions on southern Africa. South Africa's daily infections have since risen to around 20,000 in recent days.

Based on analysis by Discovery's clinical research and actuarial teams, and in collaboration with South Africa's Medical Research Council (SAMRC), the real-world study calculated that two doses of Pfizer-BioNTech offered 70per cent protection against hospitalisation during the recent surge in cases and 33 per cent protection against infection.

South Africa is using the Pfizer-BioNTech and Johnson & Johnson vaccines in its COVID-19 immunisation campaign, with more than 20 million Pfizer doses administered so far.
 

Adblock test (Why?)


https://news.google.com/__i/rss/rd/articles/CBMibWh0dHBzOi8vd3d3LmNoYW5uZWxuZXdzYXNpYS5jb20vd29ybGQvb21pY3Jvbi13YXZlLWNvdmlkLTE5LXZhY2NpbmUtcGZpemVyLXByb3RlY3Rpb24taG9zcGl0YWxpc2F0aW9uLTIzNzg4MDHSAQA?oc=5

2021-12-14 09:34:00Z
1202955929

Firms in Chinese manufacturing hub suspend operations amid COVID-19 outbreak - CNA

SHANGHAI: Multiple companies have suspended operations in one of China's biggest manufacturing hubs as local authorities try to contain a COVID-19 outbreak, halting production of goods from batteries to textile dyes and plastics.
 
At least 20 listed companies have shut operations in virus-hit areas in Zhejiang, an eastern province with a large industrial sector that accounts for around 6 per cent of China's GDP and where many goods are manufactured for export.
 
Tens of thousands of Zhejiang residents are in quarantine and some domestic flights have been suspended as a national health official said the outbreak in three cities - Ningbo, Shaoxing and Hangzhou - was developing at a "relatively rapid" speed.
 
The three cities accounted for more than 50 per cent of the province's economic output of around 6.46 trillion yuan (US$1.02 trillion) last year.
 
Zhejiang reported 44 locally transmitted cases with confirmed symptoms on Dec 13, official data showed on Tuesday, taking the total to 217 just over a week since the first case was reported on Dec 6. Prior to the current outbreak, the province had reported just one local case this year.
 
Companies reporting suspended production on Tuesday included Zhejiang Mustang Battery, Guobang Pharma and textile dyes maker Zhejiang Runtu.

Ningo-based Mustang Battery said it expected the outbreak to be brought under control very soon, and the production suspension was a temporary measure that "will not have a long-term negative impact on the company's growth."
 
Zhejiang Runtu said all its units in the Zhejiang Shangyu Economic Development Zone (SEDZ), which accounts for 95 per cent of its revenue, had been halted since Dec 9 and it expected a negative impact on its fourth quarter results.
 
There are more than 350 industrial enterprises in the zone, which is located near the cities of Ningbo, Hangzhou, Shanghai, Suzhou and Wenzhou.
 
Ningbo Homelink Eco-Itech, Zhejiang Zhongxin Fluoride Materials, Zhejiang Jingsheng Mechanical & Electrical and Zhejiang Fenglong Electric have also suspended work in affected areas.

The companies said they halted operations in line with local government orders in Zhenhai district in Ningbo and Shangyu district in Shaoxing, which curtailed all production bar essential manufacturing.
 
The orders cover all companies in the affected areas, but only listed firms are required to disclose any impact on their business.
 
Major industries in Zhenhai, which has a port, include manufacturing of precision machinery and chemicals. The district also hosts factories with investments by more than 700 foreign companies including LG Electronics and Toshiba, according to the Zhenhai government's website.

Sinopec's Zhenhai Refining and Chemicals, the biggest oil refinery in China, said on Tuesday it was maintaining a high operational rate despite tightened COVID measures. The refinery, which has annual crude oil refining capacity of 460,000 barrels-per-day, is currently processing 60,000 tonnes of crude oil each day, the company said in statement.
 
More than 50,000 people have been quarantined at centralised facilities across the coastal province of 64.4 million, while a further nearly half a million people were being monitored.

Adblock test (Why?)


https://news.google.com/__i/rss/rd/articles/CBMiXWh0dHBzOi8vd3d3LmNoYW5uZWxuZXdzYXNpYS5jb20vYXNpYS9wcm9kdWN0aW9uLXN1c3BlbnNpb25zLWNoaW5lc2UtbWFudWZhY3R1cmluZy1odWItMjM3ODMxNtIBAA?oc=5

2021-12-14 08:06:13Z
1207673875

Senin, 13 Desember 2021

China's Brii says its COVID-19 antibody cocktail retains activity against Omicron - CNA

BEIJING: China's Brii Biosciences said on Sunday (Dec 12) lab studies showed that its COVID-19 antibody cocktail retained activity against the Omicron variant, although one of the antibodies showed a substantial drop in activity when tested alone.

Test details for the dual-antibody treatment, which last week became the first approved COVID-19 antibody cocktail in China, would not be available until publication in a scientific journal, but results from three independent labs showed similar pattern, Brii chief executive Hong Zhi said on Monday.

Although no purchase order for the treatment has been announced, the firm was able to secure manufacturing capacity of 1 million doses for 2022 and 2023 each, Hong said in an investor call, adding it already has about 80,000 doses available in its inventory.

Hong said the firm hoped to receive stockpiling orders for the antibody combination. "Those are very important for us as a small company to really manage our cash flow at the same time addressing a public pandemic."

The firm, yet to disclose any in-house production capacity for the drug, is partnering with WuXi Biologics for manufacturing.

Adblock test (Why?)


https://news.google.com/__i/rss/rd/articles/CBMifWh0dHBzOi8vd3d3LmNoYW5uZWxuZXdzYXNpYS5jb20vYXNpYS9jaGluYXMtYnJpaS1zYXlzLWl0cy1jb3ZpZC0xOS1hbnRpYm9keS1jb2NrdGFpbC1yZXRhaW5zLWFjdGl2aXR5LWFnYWluc3Qtb21pY3Jvbi0yMzc1ODM20gEA?oc=5

2021-12-13 05:23:05Z
CBMifWh0dHBzOi8vd3d3LmNoYW5uZWxuZXdzYXNpYS5jb20vYXNpYS9jaGluYXMtYnJpaS1zYXlzLWl0cy1jb3ZpZC0xOS1hbnRpYm9keS1jb2NrdGFpbC1yZXRhaW5zLWFjdGl2aXR5LWFnYWluc3Qtb21pY3Jvbi0yMzc1ODM20gEA

Minggu, 12 Desember 2021

Some Chinese companies suspend production in Zhejiang province on virus outbreak - CNA

SHANGHAI: More than a dozen Chinese-listed companies said they had suspended production in coronavirus-hit parts of China's eastern Zhejiang province in response to local government's tightened COVID-19 curbs, causing their share prices to plunge.

Zhejiang reported a total of 173 locally transmitted cases with confirmed symptoms during the Dec 6 to 12 period, official numbers showed on Monday (Dec 13), marking the province's first domestic cluster outbreak this year.

In October, the province reported just one local case.

A slew of companies, including Ningbo Homelink Eco-Itech, Zhejiang Zhongxin Fluoride Materials, Zhejiang Jingsheng Mechanical & Electrical and Zhejiang Fenglong Electric, announced the production suspension through exchange filings over the weekend.

Their shares fell sharply in early trading on Monday. Zhejiang Chunhui Intelligent Control and Zhejiang Yankon Group suffered the biggest losses, with their shares falling more than 7 per cent each.

China reported 80 new locally transmitted cases with symptoms on the mainland on Dec 12, including 74 identified in Zhejiang.

Ningbo Homelink, which makes plastic products, said in an exchange filing late on Sunday that it had halted production in its home city Ningbo at the request of local authorities, and is taking measures to minimise the negative impact on its business.

Zhejiang Jindun Fans, a Chinese maker of ventilation system equipment, said on Sunday that production at its subsidiary in Zhejiang's Shaoxing city had been suspended due to local government's anti-virus measures.

The company said there would be some delay in product deliveries and a hit to business this month, but that the fallout on this year's annual results would be limited.

All the companies that announced production halt vowed to fully cooperate with the local government, which will decide when production can be resumed.

Adblock test (Why?)


https://news.google.com/__i/rss/rd/articles/CBMie2h0dHBzOi8vd3d3LmNoYW5uZWxuZXdzYXNpYS5jb20vYnVzaW5lc3Mvc29tZS1jaGluZXNlLWNvbXBhbmllcy1zdXNwZW5kLXByb2R1Y3Rpb24temhlamlhbmctcHJvdmluY2UtdmlydXMtb3V0YnJlYWstMjM3NTUzNtIBAA?oc=5

2021-12-13 03:28:56Z
CBMie2h0dHBzOi8vd3d3LmNoYW5uZWxuZXdzYXNpYS5jb20vYnVzaW5lc3Mvc29tZS1jaGluZXNlLWNvbXBhbmllcy1zdXNwZW5kLXByb2R1Y3Rpb24temhlamlhbmctcHJvdmluY2UtdmlydXMtb3V0YnJlYWstMjM3NTUzNtIBAA

South Korea to test AI-powered facial recognition to track COVID-19 cases - CNA

SEOUL: South Korea will soon roll out a pilot project to use artificial intelligence, facial recognition and thousands of CCTV cameras to track the movement of people infected with the coronavirus, despite concerns about the invasion of privacy.

The nationally funded project in Bucheon, one of the country's most densely populated cities on the outskirts of Seoul, is due to become operational in January, a city official told Reuters.

The system uses a AI algorithms and facial recognition technology to analyse footage gathered by more than 10,820 CCTV cameras and track an infected person’s movements, anyone they had close contact with, and whether they were wearing a mask, according to a 110-page business plan from the city submitted to the Ministry of Science and ICT (Information and Communications Technology), and provided to Reuters by a parliamentary lawmaker critical of the project.

Governments around the world have turned to new technologies and expanded legal powers to try to stem the tide of COVID-19 infections.

China, Russia, India, Poland and Japan as well as several US states are among the governments to have rolled out or at least experimented with facial recognition systems for tracking COVID-19 patients, according to a March report by Columbia Law School in New York.

The Bucheon official said the system should reduce the strain on overworked tracing teams in a city with a population of more than 800,000 people, and help use the teams more efficiently and accurately.

South Korea already has an aggressive, high-tech contact tracing system that harvests credit card records, cellphone location data and CCTV footage, among other personal information.

It still relies, however, on a large number of epidemiological investigators, who often have to work 24-hour shifts, frantically tracing and contacting potential coronavirus cases.

In bidding for national funding for the pilot project in late 2020, Bucheon mayor Jang Deog-cheon argued that such a system would make tracing faster.

"It sometimes takes hours to analyse a single CCTV footage. Using visual recognition technology will enable that analysis in an instant," he said on Twitter.

The system is also designed to overcome the fact that tracing teams have to rely heavily on the testimony of COVID-19 patients, who aren't always truthful about their activities and whereabouts, the plan said.

The Ministry of Science and ICT said it has no current plans to expand the project to the national level. It said the purpose of the system was to digitise some of the manual labour that contact tracers currently have to carry out.

The Bucheon system can simultaneously track up to 10 people in five to 10 minutes, cutting the time spent on manual work that takes around half an hour to one hour to trace one person, the plan said.

The pilot plans call for a team of about 10 staff at one public health centre to use the AI-powered recognition system, the official said.

Bucheon received 1.6 billion won (US$1.36 million) from the Ministry of Science and ICT and injected 500 million won of the city budget into the project to build the system, the Bucheon official said.

"BIG BROTHER"

While there has been wide public support for existing invasive track and trace methods, human rights advocates and some South Korean lawmakers have expressed concerns that the government will retain and harness such data far beyond the needs of the pandemic.

"The government's plan to become a Big Brother on the pretext of COVID is a neo-totalitarian idea," Park Dae-chul, a lawmaker from the main opposition People Power Party, told Reuters.

"It is absolutely wrong to monitor and control the public via CCTV using taxpayers' money and without the consent from the public," said Park, who provided the city plan to Reuters.

The Bucheon official said there are no privacy concerns because the system places a mosaic over the faces of anyone who is not a subject.

“There is no privacy issue here as the system traces the confirmed patient based on the Infectious Disease Control and Prevention Act,” the official told Reuters. “Contact tracers stick to that rule so there is no risk of data spill or invasion of privacy.”

Rules say patients must give their consent for the facial recognition tracking to be used, but even if they don't consent, the system can still track them using their silhouette and clothes, the official said.

The Korea Disease Control and Prevention Agency (KDCA) said the use of such technology is lawful as long as it is used within the realm of the disease control and prevention law.

The plans for AI-powered facial recognition sweeps comes as the country experiments with other uses of the controversial technology, from detecting child abuse at day cares to providing police protection.

Adblock test (Why?)


https://news.google.com/__i/rss/rd/articles/CBMicGh0dHBzOi8vd3d3LmNoYW5uZWxuZXdzYXNpYS5jb20vYXNpYS9zb3V0aC1rb3JlYS10ZXN0LWFpLXBvd2VyZWQtZmFjaWFsLXJlY29nbml0aW9uLXRyYWNrLWNvdmlkLTE5LWNhc2VzLTIzNzU0NDHSAQA?oc=5

2021-12-13 00:37:09Z
CBMicGh0dHBzOi8vd3d3LmNoYW5uZWxuZXdzYXNpYS5jb20vYXNpYS9zb3V0aC1rb3JlYS10ZXN0LWFpLXBvd2VyZWQtZmFjaWFsLXJlY29nbml0aW9uLXRyYWNrLWNvdmlkLTE5LWNhc2VzLTIzNzU0NDHSAQA

Israeli study finds Pfizer Covid-19 booster protects against Omicron - The Straits Times

JERUSALEM (REUTERS) - Israeli researchers said on Saturday (Dec 11) they found that a three-shot course of the Pfizer/BioNTech Covid-19 vaccine provided significant protection against the new Omicron variant.

The findings were similar to those presented by BioNTech and Pfizer earlier in the week, which were an early signal that booster shots could be key to protection against infection from the newly identified variant.

The study, carried out by Sheba Medical Centre and the Health Ministry's Central Virology Laboratory, compared the blood of 20 people who had received two vaccine doses five to six months earlier to the same number of individuals who had received a booster a month before.

"People who received the second dose five or six months ago do not have any neutralisation ability against the Omicron, while they do have some against the Delta (strain)," Professor Gili Regev-Yochay, director of the Infectious Diseases Unit at Sheba, told reporters.

"The good news is that with the booster dose, it increases about a hundredfold. There is a significant protection of the booster dose. It is lower than the neutralisation ability against the Delta, about four times lower," she said.

The Israeli team said they worked with the actual virus while the companies used what is known as a pseudovirus, which was bio-engineered to have the hallmark mutations of Omicron.

The Israeli research follows a study from South Africa that found the Omicron variant can partially evade protection from two doses.

Related Stories: 

Adblock test (Why?)


https://news.google.com/__i/rss/rd/articles/CBMic2h0dHBzOi8vd3d3LnN0cmFpdHN0aW1lcy5jb20vd29ybGQvbWlkZGxlLWVhc3QvaXNyYWVsaS1zdHVkeS1maW5kcy1wZml6ZXItY292aWQtMTktYm9vc3Rlci1wcm90ZWN0cy1hZ2FpbnN0LW9taWNyb27SAQA?oc=5

2021-12-11 22:28:17Z
CAIiELpMJ5lzoZ23_feMFrihkSoqGQgEKhAIACoHCAow_7X3CjCh49YCMKWWpwU